DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

MRNA·Moderna, Inc.

$.
+. (+.%)
After Hours
High
$49.08
Open
$47.02
Market Cap
18.66B
52W High
$59.55
Low
$46.81
P. Close
$47.62
P/E
-
52W Low
$22.28
Fwd P/E
-11.19
Mean Target
$43.20
Technical Score (1D)
32
SELL
News Sentiment
58
BULLISH
Moderna's oncology pipeline is emerging as a critical focus, with the potential for its cancer vaccine candidates to significantly alter the company's market perception and drive future growth. Investors are closely monitoring clinical trial progress and upcoming data readouts, as these advancements are expected to validate the therapeutic promise of its platform. The market sentiment surrounding Moderna is increasingly hinging on these pipeline developments, suggesting a shift in focus from recent stock underperformance to the long-term valuation potential of its oncology efforts.
Earnings Summary
Moderna, Inc. is a biotechnology firm focused on developing and commercializing messenger RNA (mRNA) medicines, including vaccines and therapeutics across various areas such as respiratory illnesses, oncology, and rare diseases. Operating within the dynamic Biotechnology industry in the Healthcare sector, Moderna leverages strategic partnerships to advance its extensive pipeline of mRNA candidates. The company's recent performance shows a trend of improving earnings per share (EPS) misses, moving from -2.91 in Q4 2024 to -0.51 in Q3 2025, and further to -1.18 in Q1 2026, indicating a deceleration in the magnitude of negative EPS relative to estimates. Revenue performance has been more volatile, with significant fluctuations such as a drop to $108 million in Q1 2025 followed by a substantial increase to $1.016 billion in Q3 2025, and then $678 million in Q4 2025 and $389 million in Q1 2026. Historically, Moderna has shown a pattern of revenue growth in certain quarters, such as the increase from Q2 2025 to Q3 2025, despite consistent EPS misses against analyst expectations. For instance, Q3 2025 saw actual EPS of -0.51 significantly outperform the estimated -2.17919, while revenue reached $1.016 billion. Recent news highlights critical developments, including an upcoming FDA advisory committee review for its mRNA flu vaccine on June 18, a key regulatory milestone, and amendments to its bylaws mandating Securities Act lawsuits be filed in U.S. federal district courts. These events occur as the company navigates a post-COVID revenue transition, with annual sales having declined significantly. Investors will be watching for the outcome of the flu vaccine review and the progress of its personalized cancer vaccine program with Merck, which is considered a significant 2026 catalyst, to gauge future revenue streams and the company's ability to scale new products beyond its COVID-19 offerings.

EPS

EstBeatMiss
$-3.58$-2.71$-1.84$-0.98$-0.11Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$-2.00 - -
Q1'26$-1.96$-1.18+39.6%
Q4'25$-2.18$-2.11+3.4%
Q3'25$-2.18$-0.51+76.6%
Q2'25$-2.97$-2.13+28.3%
Q1'25$-3.18$-2.52+20.7%

Revenue

EstBeatMiss
$-46M$254M$554M$854M$1.2BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$104M - -
Q1'26$92M$389M+321.1%
Q4'25$254M$678M+167.1%
Q3'25 - $1.0B -
Q2'25 - $142M -
Q1'25 - $108M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

MRNA Stock Snapshot

MRNA is currently trading at $47.74, giving Moderna, Inc. a market cap of 18.66B. Today's range spans $46.81–$49.08, with shares opening at $47.02 and moving up $0.12 (0.3%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 58/100.

Over the past year MRNA has traded between $22.28 and $59.55 - the current price is +114.3% off the 52-week low and -19.8% from the high. 30 analysts cover the stock with a Hold consensus and a mean 12-month target of $43.20 (range $21.00–$69.00), implying downside of -9.5%.

The bearish momentum on Moderna, Inc. (MRNA) - 32/100 (SELL), sentiment neutral at 58/100, price $47.74 (in the upper portion of its 52-week range) - is the type of setup where stop-loss selling from long-side momentum strategies amplifies the initial technical weakness. At 18.66B in Healthcare market cap, the 52-week range of $22.28–$59.55 provides the structural reference, and the lower end of that range becomes the next key test if the current SELL signal persists.

Analyst coverage for MRNA becomes a double-edged factor in a SELL phase: at 18.66B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 32/100 technical reading and neutral sentiment (58/100) at $47.74 (in the upper portion of its 52-week range) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $22.28–$59.55 range establishes where that repricing lands.